The Ministry of Food and Drug Safety said Novo Nordisk's obesity injection "Wigobi," which will be released in Korea this month, should be carefully used according to medical professionals' prescriptions and approved usage only for highly obese patients.
The injection is a specialized drug for adult obese patients and is known to have side effects such as headache, diarrhea, constipation, cholelithiasis, hair loss, and acute pancreatitis.
In addition, patients with diabetes or hypoglycemia may occur due to deterioration of kidney function due to dehydration, so patients with the disease should be carefully administered.
The Ministry of Food and Drug Safety urged people not to buy the obesity treatment online without being prescribed, and emphasized that it plans to check over-advertising behavior in medical institutions.
※ 'Your report becomes news'
[Kakao Talk] YTN Search and Add Channel
[Phone] 02-398-8585
[Mail] social@ytn.co.kr
[Copyright holder (c) YTN Unauthorized reproduction, redistribution and use of AI data prohibited]
Society
View the full list of articles- 'Devil's Smile' Killer Park Dae-sung Is Death Penalty Hard? "There's a case of a premeditated crime, but..."
- Police "Scheduling the investigation of Moon Da-hye..."Follow the General Procedures"
- About 200 people charged with violating election laws in Seoul will be sent to the general election in April.
- 70s on the Gyeongin Expressway 'reverse driving' car...the idea of five people